Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila AKK PROBIO
- Development stage
- Unknown
- Lead developer
- Thankcome Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Akkermansia muciniphila AKK PROBIO is a live biotherapeutic probiotic formulation containing the Gram-negative, anaerobic bacterium *Akkermansia muciniphila*. It is currently being evaluated in clinical trials for the treatment of obesity, dyslipidemia, and impaired glucose metabolism. *A. muciniphila* naturally inhabits the mucus layer of the human gut, where it degrades mucin to produce beneficial short-chain fatty acids (SCFAs) like acetate and propionate. The mechanism of action involves enhancing gut barrier integrity, thereby reducing the translocation of pro-inflammatory lipopolysaccharides (LPS) into the bloodstream (metabolic endotoxemia). Additionally, specific membrane proteins of the bacterium, such as Amuc_1100, have been shown to interact with Toll-like receptor 2 (TLR2) to improve insulin sensitivity and glucose homeostasis.
- Other names
- Akkermansia muciniphila
02
Targets
TLR2 (Toll-like Receptor 2)ICAM2 (Intercellular adhesion molecule 2 (ICAM-2))TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Akkermansia muciniphila AKK PROBIO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila AKK PROBIO.